DOCSLIB.ORG

Potentially Serious Alcohol–Medication Interactions in Older Adults) Criteria

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potentially Serious Alcohol–Medication Interactions in Older Adults) Criteria Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-017453 on 8 November 2017. Downloaded from Consensus validation of the POSAMINO (POtentially Serious Alcohol–Medication INteractions in Older adults) criteria Alice E Holton,1 Paul J Gallagher,1 Cristín Ryan,1 Tom Fahey,2 Gráinne Cousins1 To cite: Holton AE, Gallagher PJ, ABSTRACT Strengths and limitations of this study Ryan C, et al. Consensus Objectives Older adults are particularly vulnerable to validation of the POSAMINO adverse effects from concurrent alcohol and medication ► The POtentially Serious Alcohol–Medication (POtentially Serious Alcohol– use. However, there is limited evidence regarding the Medication INteractions in INteractions in Older adults criteria were developed prevalence of these adverse outcomes among older adults, Older adults) criteria. BMJ Open in a robust fashion, using a two-step process and there is a lack of consensus regarding what constitutes 2017;7:e017453. doi:10.1136/ involving a systematic review and two-round Delphi an alcohol-interactive medicine. The objective of this study bmjopen-2017-017453 process. was to develop an explicit list of potentially serious alcohol– ► The Delphi consensus technique used in this study is ► Prepublication history and medication interactions for use in older adults. flexible and enabled communication from a diverse additional material for this Design Following a systematic review, review of drug paper are available online. To group of healthcare professionals from both the UK compendia and clinical guidance documents, a two-round view these files, please visit and Ireland. Delphi consensus method was conducted. the journal online (http:// dx. doi. ► The final criteria will need to be further validated Setting Ireland and the United Kingdom (UK), primary care org/ 10. 1136/ bmjopen- 2017- prospectively to quantify the magnitude of risk and hospital setting. 017453). posed for each criterion for adverse outcomes in Participants The Project Steering Group developed a older adults. Received 23 April 2017 list of potentially serious alcohol–medication interactions. ► Once validated, these criteria have the potential Revised 6 September 2017 The Delphi panel consisted of 19 healthcare professionals to inform medical decision making and enable Accepted 11 September 2017 (general practitioners, geriatricians, hospital and healthcare professionals to risk stratify older adults community pharmacists, clinical pharmacologists and at the point of prescribing and prioritise alcohol pharmacists, and physicians specialising in substance http://bmjopen.bmj.com/ screening and brief interventions in high-risk groups. misuse). Results An inventory of 52 potentially serious alcohol– medication interactions was developed by the Project Steering 1 Group. British National Formulary black dot warnings (n=8) population continuing to increase. While were included in the final criteria as they represent ‘potentially alcohol consumption tends to decline with serious’ interactions. The remaining 44 criteria underwent a age, older adults are inclined to drink more 2 two-round Delphi process. In the first round, 13 criteria were frequently. Ageing is associated with a variety accepted into the POtentially Serious Alcohol–Medication of physiological changes, which may place INteractions in Older adults (POSAMINO) criteria. Consensus older adults at an increased risk of alcohol-re- on September 26, 2021 by guest. Protected copyright. was not reached on the remaining 31 criteria; 9 were lated health problems.3 4 In fact, compared removed and 8 additional criteria were included following a with younger adults, they encounter a dispro- review of panellist comments. The remaining 30 criteria went portionate burden of alcohol-related harm, to round 2, with 17 criteria reaching consensus, providing with reported alcohol-related deaths highest a final list of 38 potentially serious alcohol–medication among those aged 55 to 74 years in England interactions: central nervous system (n=15), cardiovascular 4 system (n=9), endocrine system (n=5), musculoskeletal in 2010. system (n=3), infections (n=3), malignant disease and Polypharmacy is also increasing in older 1 5 School of Pharmacy, Royal immunosuppression (n=2), and respiratory system (n=1). adults and certain medicines may interact College of Surgeons in Ireland Conclusions POSAMINO is the first set of explicit with alcohol, increasing the risk of adverse (RCSI), Dublin 2, Ireland 2Division of Population Health potentially serious alcohol–medication interactions for use events such as sedation, hypotension, gastro- Science, HRB Centre for Primary in older adults. Following future validation studies, these intestinal bleeds, hypoglycaemia and liver 6 7 Care Research, Royal College criteria may allow for the risk stratification of older adults damage. In a previous observational study, of Surgeons in Ireland (RCSI), at the point of prescribing. moderate alcohol consumption increased Dublin 2, Ireland the risk of adverse drug reactions by 24% 8 Correspondence to BACKGROUND among older adults. Alcohol interactive Alice E Holton; Population demographics are changing glob- (AI) medicines may interact with alcohol by aliceholton@ rcsi. ie ally, with the proportion and age of the older altering the effects (pharmacodynamic) or Holton AE, et al. BMJ Open 2017;7:e017453. doi:10.1136/bmjopen-2017-017453 1 Open Access BMJ Open: first published as 10.1136/bmjopen-2017-017453 on 8 November 2017. Downloaded from metabolism (pharmacokinetic) of the medication and/ Furthermore, the British National Formulary (BNF), or alcohol.7 The interactions may occur with any alcohol Stockley’s Drug Interactions and Martindale Complete or may follow a dose response, with the severity and risk Drug Reference drug compendia were also searched.11–13 of interactions increasing with increasing levels of alcohol Additional documents such as clinical guidance docu- consumption.6 ments14 and previous reviews6 7 were also accessed. While a number of studies have investigated the Information extracted included medication name/class, concurrent use of alcohol and AI medicines among older potential adverse outcome(s), whether an interaction is adults,9 there is still a lack of agreement regarding the likely to occur with any alcohol consumption or with heavy inclusion of AI medicines across studies. Several studies consumption using national low risk drinking guide- have reported on a broad range of medication classes, lines15 16 and, if reported, evidence supporting the inter- using different drug reference sources and software to action. The list of medications was organised according identify medications as AI, thus leading to a lack of consis- to the BNF physiological classification system. There was tency in the inclusion of these medicines.9 Other studies considerable heterogeneity across reference sources in focused on psychotropic medications alone.9 terms of identifying medications as having potential to Despite the findings of our previous systematic review, interact with alcohol, with no age-specific information for highlighting a high prevalence of concurrent use among interactions. Furthermore, there were inconsistencies in older adults, no study to date has examined longitudinal relation to the quantity of concurrent alcohol consump- associations of concurrent use with adverse outcomes.9 An tion that should be avoided. For example, the Martindale evidence-based list of potentially serious alcohol–medi- mentioned that alcohol combined with non-steroidal cine interactions for older adults has potential in a clin- anti-inflammatory drugs (NSAIDs) may increase the risk ical setting, once validated, allowing for the identification of gastrointestinal bleeds with no mention of alcohol of older adults whose alcohol consumption places them consumption patterns, Stockley’s described that both at increased risk and who would benefit from a preven- NSAIDs and excessive alcohol use carry the risk of gastro- tative intervention. Therefore, the aim of this study is to intestinal adverse effects, while NSAIDs and alcohol were derive the first set of explicit potentially serious alcohol– not included as an interaction in the BNF. For the next medication interactions in older adults. step, the Project Steering Group reviewed and assessed each medication or drug class. Using the definition of ‘necessary to avoid’ previously described by Dreischulte METHODS et al,17 it was considered necessary to avoid concurrent Study design alcohol with a specific medication if, in an average older A Delphi consensus technique was used to develop the adult, concurrent use of alcohol with this medication list of potentially serious alcohol–medication interactions would be considered unsafe because (a) there is suffi- in older adults. The Delphi method allows a consensus cient evidence that the patient is likely to be harmed and http://bmjopen.bmj.com/ opinion to be reached among a panel of experts through (b) the likely harm to the patient is large enough to be an iterative process of questionnaires.10 Ethics approval clinically significant. for this study was obtained from the Royal College Drugs were excluded for the following reasons: their of Surgeons in Ireland (RCSI) (reference number interaction with alcohol was not considered serious, that REC 1097). A Project Steering Group comprising is, unlikely to cause significant harm to the patient (eg, 13 academic and clinical pharmacists, a general practitioner selective serotonin
Load more

Recommended publications
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name
    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
    [Show full text]
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Exforge HCT in Patients with These Highlights Do Not Include All the Information Needed to Use Diabetes (4) EXFORGE HCT Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION Do not coadminister aliskiren with Exforge HCT in patients with These highlights do not include all the information needed to use diabetes (4) EXFORGE HCT safely and effectively. See full prescribing information for EXFORGE HCT. -----------------------WARNINGS AND PRECAUTIONS ----------------------- Hypotension: Correct volume depletion prior to initiation (5.2) ® EXFORGE HCT (amlodipine, valsartan, and hydrochlorothiazide) Increased angina and/or myocardial infarction (5.3) tablets, for oral use Monitor renal function and potassium in susceptible patients (5.4, 5.5) Initial U.S. Approval: 2009 Exacerbation or activation of systemic lupus erythematosus (5.7) WARNING: FETAL TOXICITY Observe for signs of fluid or electrolyte imbalance (5.9) See full prescribing information for complete boxed warning. Acute angle-closure glaucoma (5.10) When pregnancy is detected, discontinue Exforge HCT as soon as possible. (5.1) ------------------------------ADVERSE REACTIONS ------------------------------ Drugs that act directly on the renin-angiotensin system can cause Most common adverse events (≥ 2% incidence) are dizziness, peripheral injury and death to the developing fetus. (5.1) edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea, and nasopharyngitis. (6.1) ---------------------------INDICATIONS AND USAGE --------------------------- Exforge HCT is a combination tablet of amlodipine, a dihydropyridine To report SUSPECTED ADVERSE REACTIONS, contact Novartis calcium channel blocker (DHP CCB), valsartan, an angiotensin II receptor Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA- blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Exforge HCT is 1088 or www.fda.gov/medwatch. indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, ------------------------------DRUG INTERACTIONS ------------------------------ primarily strokes, and myocardial infarctions.
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]
  • Karger AG, Basel Published Online: November 26, 2018 by S
    Neurosignals 2018;26:77-93 DOI: 10.1159/000495425 © 2018 The Author(s).© 2018 Published The Author(s) by S. Karger AG, Basel Published online: November 26, 2018 www.karger.com/nsgPublished by S. Karger AG, Basel 77 www.karger.com/nsg Accepted:Hundehege November et al.: Pregabalin 08, 2018 in Experimental Autoimmune Encephalitis This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Original Paper Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis Petra Hundehegea Juncal Fernandez-Ortha Pia Römera Tobias Rucka Thomas Münteferinga Susann Eichlera Manuela Cerinaa Lisa Eppinga Sarah Albrechta Amélie F. Menkea Katharina Birknerb Kerstin Göbela Thomas Buddec Frauke Zippb Heinz Wiendla Ali Gorjid Stefan Bittnerb Sven G. Meutha aNeurology Department with Institute of Translational Neurology, University of Münster, bDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, cInstitute of Physiology I, University of Münster, dNeurology Department with Institute of Translational Neurology and Neurosurgery Department, University of Münster, Germany Key Words Multiple sclerosis • Pregabalin • Experimental autoimmune encephalomyelitis • Neuroprotection Abstract Background/Aims: Multiple sclerosis (MS) is a prototypical autoimmune central nervous system (CNS) disease. Particularly progressive forms of MS (PMS) show significant neuroaxonal damage as consequence of demyelination and neuronal hyperexcitation. Immuno-modulatory treatment strategies are beneficial in relapsing MS (RMS), but mostly fail in PMS.
    [Show full text]
  • Comparing the Efficacy of Angiotensin Converting Enzyme In- Hibitors with Calcium Channel Blockers on the Treatment of Di- Abetic Nephropathy: a Meta-Analysis
    Iran J Public Health, Vol. 48, No.2, Feb 2019, pp.189-197 Review Article Comparing the Efficacy of Angiotensin Converting Enzyme In- hibitors with Calcium Channel Blockers on the Treatment of Di- abetic Nephropathy: A Meta-Analysis *Zhaowei ZHANG 1, Chunlin CHEN 2, Shiwen LV 1, Yalan ZHU 1, Tianzi FANG 1 1. Department of Pharmacy, Jin Hua Municipal Central Hospital, Jin Hua 32100, China 2. College of Chemistry and Bio-Engineering, Yi Chun University, Yi Chun 336000, China *Corresponding Author: Email: [email protected] (Received 21 Mar 2018; accepted 11 Jun 2018) Abstract Background: The angiotensin-converting enzyme inhibitors (ACEIs) could improve the symptoms of diabetic nephropathy. Whether the calcium channel blockers (CCBs) could be as effective as ACEIs on treating diabetic nephropathy is controversial. Here, we aimed to compare the efficacy of ACEIs with CCBs on the treatment of diabetic nephropathy by performing a meta-analysis of randomized controlled trials (RCTs). Methods: The Pubmed, Medline, Embase and The Cochrane Database were searched up to July 2017 for eli- gible randomized clinical trials studies. Effect sizes were summarized as mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (P-value<0.05). Results: Seven RCTs involving 430 participants comparing ACEIs with CCBs were included. No benefit was seen in comparative group of ACEIs on systolic blood pressure（SBP） (MD=1.05 mmHg; 95% CI: -0.97 to 3.08, P=0.31), diastolic blood pressure (DBP) (MD= -0.34 mmHg; 95% CI: -1.2 to 0.51, P=0.43), urinary al- bumin excretion rates (UAER) (MD=1.91μg/min; 95% CI: -10.3 to 14.12, P=0.76), 24-h urine protein (24-UP) (SMD=-0.26; 95%CI: -0.55 to 0.03, P=0.08), glomerular filtration rate (GFR) (SMD=0.01; 95% CI: -0.38 to 0.41, P=0.95).
    [Show full text]
  • AMILORIDE HYDROCHLORIDE and HYDROCHLOROTHIAZIDE- Amiloride Hydrochloride and Hydrochlorothiazide Tablet Mylan Pharmaceuticals Inc
    AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE- amiloride hydrochloride and hydrochlorothiazide tablet Mylan Pharmaceuticals Inc. ---------- DESCRIPTION Amiloride hydrochloride and hydrochlorothiazide tablets, USP combine the potassium- conserving action of amiloride hydrochloride with the natriuretic action of hydrochlorothiazide. Amiloride hydrochloride is designated chemically as 3,5-diamino-6-chloro-N-(diamino- methylene)pyrazinecarboxamide monohydrochloride, dihydrate. It has the following structural formula: C6H8ClN7O•HCl•2H2O MW = 302.12 Hydrochlorothiazide is designated chemically as 6-chloro-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide 1,1-dioxide. It has the following structural formula: C7H8ClN3O4S2 MW = 297.74 It is a white, or practically white, crystalline powder which is slightly soluble in water, but freely soluble in sodium hydroxide solution. Each tablet, for oral administration, contains 5 mg of amiloride hydrochloride, USP (calculated on the anhydrous basis) and 50 mg of hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients: croscarmellose sodium, FD&C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, pregelatinized starch (corn), and sodium lauryl sulfate. CLINICAL PHARMACOLOGY Amiloride hydrochloride and hydrochlorothiazide tablets provide diuretic and antihypertensive activity (principally due to the hydrochlorothiazide component), while acting through the amiloride component to prevent the excessive potassium loss that may occur in patients receiving
    [Show full text]
  • Actual Place of Diuretics in Hypertension Treatment
    Mini Review J Cardiol & Cardiovasc Ther Volume 3 Issue 4 - March 2017 Copyright © All rights are reserved by Farouk Abcha DOI: 10.19080/JOCCT.2017.03.555616 Actual Place of Diuretics in Hypertension Treatment Farouk Abcha, Marouane Boukhris*, Zied Ibn Elhadj, Lobna Laroussi, Faouzi Addad, Afef Ben Halima and Salem Kachboura Cardiology Department of Abderrahmen Mami Hospital, University of Tunis El Manar, Tunisia Submission: February 03, 2017; Published: March 07, 2017 *Corresponding author: Marouane Boukhris, Cardiology Department of Abderrahmen Mami Hospital, Ariana, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia, Tel: ; Email: Abstract Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment. In the current editorial, we assessed the actual place of different diuretics in the hypertension guidelines focusing on the concept of tailored approach in prescribing them for hypertensive patients. Keywords: Diuretics; Hypertension; Hydrochlorothiazide; Indapamide; Guidelines Introduction Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment [1]. Indeed, they are the second most commonly prescribed class of antihypertensive medication. For instance, 12% of US adults were prescribed a diuretic, and the relative increase in prescriptions from 1999 through 2012 was 1.4 [2].
    [Show full text]
  • Ambetter 90-Day-Maintenance Drug List- 2020
    Ambetter 90-Day-Maintenance Drug List Guide to this list: What is Ambetter 90‐Day‐Maintenance Drug List? Ambetter 90‐Day‐Supply Maintenance Drug List is a list of maintenance medications that are available for 90 day supply through mail order or through our Extended Day Supply Network. How do I find a pharmacy that is participating in Extended Day Supply Network? To find a retail pharmacy that is participating in our Extended Day Supply Network please consult information available under Pharmacy Resources tab on our webpage. Alternatively, you can utilize our mail order pharmacy. Information on mail order pharmacy is available in Pharmacy Resources tab on our webpage. Are all formulary drugs covered for 90 day supply? No, certain specialty and non‐specialty drugs are excluded from 90 day supply. Please consult 90‐Day‐ Supply Maintenance Drug List for information if your drug is included. A Amitriptyline HCl Acamprosate Calcium Amlodipine Besylate Acarbose Amlodipine Besylate-Atorvastatin Calcium Acebutolol HCl Amlodipine Besylate-Benazepril HCl Acetazolamide Amlodipine Besylate-Olmesartan Medoxomil Albuterol Sulfate Amlodipine Besylate-Valsartan Alendronate Sodium Amlodipine-Valsartan-Hydrochlorothiazide Alendronate Sodium-Cholecalciferol Amoxapine Alfuzosin HCl Amphetamine-Dextroamphetamine Aliskiren Fumarate Anagrelide HCl Allopurinol Anastrozole Alogliptin Benzoate Apixaban Alosetron HCl Arformoterol Tartrate Amantadine HCl Aripiprazole Amiloride & Hydrochlorothiazide Armodafinil Amiloride HCl Asenapine Maleate Amiodarone HCl Aspirin-Dipyridamole
    [Show full text]
  • FDA's) Current Thinking on This Topic
    Contains Nonbinding Recommendations Draft Guidance on Amiloride Hydrochloride This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs. Active ingredient: Amiloride Hydrochloride Form/Route: Tablet; Oral Recommended studies: 2 Studies 1. Type of study: Fasting Design: Single-dose, two-way crossover in-vivo Strength: EQ 5 mg Base Subjects: Healthy males, nonpregnant females and non-elderly, general population. Additional Comments: Subjects with impaired renal function, diabetes mellitus, should be excluded from the study. As amiloride treatment may cause hyperkalemia, serum potassium levels should be monitored carefully during the bioequivalence study. ________________________________________________________________________ 2. Type of study: Fed Design: Single-dose, two-way crossover in-vivo Strength: EQ 5 mg Base Subjects: Healthy males, nonpregnant females and non-elderly, general population. Additional Comments: Please see above. ________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Amiloride in plasma Bioequivalence based on (90% CI): Amiloride Waiver request of in-vivo testing: Not applicable Dissolution test method and sampling times: Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products.
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]